POS0260 ONCE-MONTHLY SEL-212 DEMONSTRATES EFFICACY AND SAFETY FOR UP TO 6-MONTHS IN GOUT REFRACTORY TO CONVENTIONAL THERAPY: COMBINED DATA FROM THE DISSOLVE I & II PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIALS